IDH1 and glioblastoma: A recent TCGA effort utilised methylation profiling to identify a GBM CpG island methylator phenotype (G-CIMP) in a significant fraction (29%) of proneural GBM, particularly secondary, IDH1 mutation-positive GBM that progressed from lower-grade tumours (Noushmehr et al, 2010).